Fly News Breaks for January 7, 2020
Jan 7, 2020 | 05:21 EDT
Piper Sandler analyst Matt O'Brien upgraded Zimmer Biomet (ZBH) to Overweight from Neutral with a price target of $170, up from $140. Upside to consensus estimates exists, which should continue to push the stock higher, O'Brien tells investors in a research note. The analyst's favorite orthopedics name for the start of the new decade is NuVasive (NUVA) as he believes there is upside to numbers, a reasonable valuation and potentially major catalyst late this year with the launch of its robotic system.
News For ZBH;NUVA From the Last 2 Days
There are no results for your query ZBH;NUVA